科兴制药：8月14日召开董事会会议

Group 1 - The core point of the article is that Kexing Pharmaceutical announced the convening of its 28th board meeting on August 14, 2025, to discuss various proposals, including the establishment of certain systems [1] - For the year 2024, Kexing Pharmaceutical's revenue composition is as follows: 99.59% from pharmaceutical manufacturing, 0.25% from other businesses, and 0.16% from other sources [1] - As of the report date, Kexing Pharmaceutical has a market capitalization of 9 billion yuan [1] Group 2 - Huakang Co., Ltd. is facing scrutiny over an 11 billion yuan acquisition, as the major client of the acquisition target has been in a debt crisis for two years, raising questions about its ability to contribute significant revenue [1]